VRML - Vermillion, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Vermillion, Inc.

Building III
Suite 100
Austin, TX 78738
United States

IndustryDiagnostic Substances
Full Time Employees33

Key Executives

Ms. Valerie Barber PalmieriChief Exec. Officer, Pres and Director450.68kN/A56
Mr. Eric J. SchoenChief Accounting Officer and Sr. VP of Fin.280.68kN/A49
Mr. Fred FerraraChief Operating Officer354.87kN/A49
Dr. Marra Francis M.D.Chief Medical OfficerN/AN/AN/A
Mr. Patrick CarpenterGen. Mang. of ASPiRA LABSN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women in the United States. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company’s products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Corporate Governance

Vermillion, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.